The latest edition of the CaHRU Newsletter (Summer 2017) was published in September 2017. The newsletter presents the work of the research centre over the previous three months and includes articles from the CaHRU blog covering publications, conferences and funding. The newsletter is written by members of the CaHRU team and produced by Sue Bowler, CaHRU administrator.
[su_document url=”https://communityandhealth.dev.lincoln.ac.uk/files/2017/09/CaHRU-Newsletter-Summer-2017.pdf” responsive=”no”]Multi-morbidity, goal-oriented care, the community and equity[/su_document]
Two key articles on development and prioritization of new ambulance performance measures were published this autumn 2017 in Health Expectations. The studies come from, Prehospital Outcomes for Evidence Based Evaluation (PhOEBE), funded by a five year National Institute for Health Research Programme Grant for Applied Health Research led by Professor Niro Siriwardena from CaHRU and Janette Turner of the Centre for Urgent and Emergency care research (CURE).
The first article, ‘Prioritizing novel and existing ambulance performance measures through expert and lay consensus: a three-stage multimethod consensus study‘ involved a multistakeholder consensus event, modified Delphi study, and patient and public consensus workshop, which together identified a shortlist of ambulance outcome and performance measures important to ambulance clinicians and service providers, service users, commissioners and academics.
The final set of measures included change in pain score, accuracy of call identification, average response time, proportion of patients with a serious condition who survived to 7 days post-admission, death (within 3 days) from a low risk condition, proportion of patients transported to the Emergency Department who were discharged without treatment or investigation, and the proportion of those with specific conditions treated according to current guidelines.
The public consensus workshop, ‘A coproduced patient and public event: An approach to developing and prioritizing ambulance performance measures‘, was effective for obtaining public feedback on which ambulance performance measures were most highly favoured by lay participants. These measures have been developed to be used in future by ambulance services or commissioners to benchmark care quality between services or regions or to measure performance over time.
By Prof Niro Siriwardena
CaHRU are pleased to announce the first publication from the Wellcome Trust funded project, NEAT: Network exploring Ethics in Ambulance Trials. The article, entitled ‘Assessment of consent models as an ethical consideration in the conduct of prehospital ambulance randomised controlled clinical trials: a systematic review‘, sought to understand the main ethical considerations when conducting clinical trials involving ambulance services.
The review found issues with consent were the most significant ethical issue for ambulance trials. The type of consent gained differed depending on the condition or intervention being studied, but the country in which the research took place had less influence on the type of consent. The terminology used to describe consent varied widely with multiple terms used to describe the same processes. This, coupled with the the wide range of consent types used led to the conclusion that standardisation of consent models and terminology used to describe them was warranted.
The systematic review was published in BMC Medical Research Methodology and is available open access at the following link: http://rdcu.be/vUxW
By Stephanie Armstrong.
A new article entitled ‘Biosimilar uptake by British local formularies: a cross sectional study‘, authored by CaHRU member Dr Murray Smith together with colleagues at the universities of Nottingham and Manchester, was published online on September 5, 2017, in the International Journal of Clinical Pharmacy – the link to the open access article is here. The article reported research examining the uptake throughout Britain of biosimilar medicines, where these are inexact copies of biological medicines no longer protected by legal patent from copying.
Increasing numbers of biosimilars are being manufactured, licensed and becoming available for use in healthcare in Britain predominantly because the biologics they seek to replace are themselves generally quite expensive for the NHS to buy. By interrogating the prescribing recommendations made in 146 local pharmaceutical formularies from NHS trusts and health boards across Britain we were able to contrast the willingness of clinicians towards prescribing a patient to a biosimilar versus that of remaining with the original biologic.
The main finding of this work is that the uptake of biosimilar medicines in Britain is generally less than would be expected especially given that its market for pharmaceuticals has typically had such a strong focus on the use of generics.
By Dr Murray Smith
The latest edition of the CaHRU Newsletter (Spring 2017) was published in June 2017. The newsletter presents the work of the research centre over the previous three months and includes articles from the CaHRU blog covering publications, conferences and funding. The newsletter is written by members of the CaHRU team and produced by Sue Bowler, CaHRU administrator.
[su_document url=”https://communityandhealth.dev.lincoln.ac.uk/files/2017/07/CaHRU-Newsletter-Spring-2017.pdf” responsive=”no”]Multi-morbidity, goal-oriented care, the community and equity[/su_document]